MDT

97.79

-1.28%↓

141.24

-3.25%↓

VEEV

221.27

+0.94%↑

HQY

86.08

-3.24%↓

NEOG

9.23

-2.43%↓

MDT

97.79

-1.28%↓

141.24

-3.25%↓

VEEV

221.27

+0.94%↑

HQY

86.08

-3.24%↓

NEOG

9.23

-2.43%↓

MDT

97.79

-1.28%↓

141.24

-3.25%↓

VEEV

221.27

+0.94%↑

HQY

86.08

-3.24%↓

NEOG

9.23

-2.43%↓

MDT

97.79

-1.28%↓

141.24

-3.25%↓

VEEV

221.27

+0.94%↑

HQY

86.08

-3.24%↓

NEOG

9.23

-2.43%↓

MDT

97.79

-1.28%↓

141.24

-3.25%↓

VEEV

221.27

+0.94%↑

HQY

86.08

-3.24%↓

NEOG

9.23

-2.43%↓

Strona główna・Stock List・Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals Inc

Open

SectorHealthcare

20.78 -1.05

Buy Sell

Overview

Share price change

24h

Current

Min

20.24

Max

21.1

Key metrics
By Trading Economics
Income	11M -61M
Sales	7.9M 46M
Profit margin	-132.36
Employees	270
EBITDA	6.3M -58M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+82.42% upside

Dividends
By Dow Jones
Next Earnings	2 mar 2026

Market Stats
By TradingEconomics
Market Cap	672M 1.8B
Previous open	21.83
Previous close	20.78

News Sentiment

By Acuity

50%

161 / 361 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

9.91 / 14.15 Support & Resistance

Syndax Pharmaceuticals Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

15 sty 2026, 18:44 UTC

Major Market Movers

Agenus Falls After $141 Million Zydus Deal Closes

15 sty 2026, 17:51 UTC

Major Market Movers

Galaxy Digital Climbs on Texas Data-Center Expansion Approval, Tokenized CLO Issuance

15 sty 2026, 17:25 UTC

Major Market Movers

ASML Exceeds $500 Billion in Market Value on TSMC's Blockbuster Spending Plans -- Update

15 sty 2026, 23:48 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

15 sty 2026, 23:48 UTC

Market Talk

Nikkei May Decline as Enthusiasm Over Election Eases -- Market Talk

15 sty 2026, 23:40 UTC

Market Talk

Gold Edges Lower Amid Abating Geopolitical Risks -- Market Talk

15 sty 2026, 23:11 UTC

Market Talk

Global Equities Roundup: Market Talk

15 sty 2026, 23:11 UTC

Market Talk

Ryman Healthcare's Resales Remain Key Concern -- Market Talk

15 sty 2026, 23:01 UTC

Market Talk

New Zealand's Economy Enters An Upswing -- Market Talk

15 sty 2026, 22:56 UTC

Market Talk

Earnings

Catalyst Metals Delivers a Beat With Record Gold Output -- Market Talk

15 sty 2026, 22:51 UTC

Market Talk

James Hardie's Plant Closures Could Boost Profit by 2%-3% -- Market Talk

15 sty 2026, 22:19 UTC

Acquisitions, Mergers, Takeovers

Verizon Gets Final California Approval to Secure $9.6 Billion Frontier Deal -- WSJ

15 sty 2026, 21:50 UTC

Market Talk

Earnings

Financial Services Roundup: Market Talk

15 sty 2026, 21:50 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Energy & Utilities Roundup: Market Talk

15 sty 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

15 sty 2026, 21:27 UTC

Earnings

BlackRock Caps 2025 With Record $14 Trillion in Assets -- 3rd Update

15 sty 2026, 21:15 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Global Commodities Roundup: Market Talk

15 sty 2026, 21:11 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Global Equities Roundup: Market Talk

15 sty 2026, 21:11 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Canada Antitrust Watchdog Confirms Review of Canadian Energy Deal -- Market Talk

15 sty 2026, 20:10 UTC

Market Talk

U.S. Natural Gas Futures Settle Mixed -- Market Talk

15 sty 2026, 20:04 UTC

Earnings

These Stocks Are Today's Movers: TSMC, ASML, Goldman, Morgan Stanley, BlackRock, Coinbase, Sandisk, and More -- Barrons.com

15 sty 2026, 20:03 UTC

Market Talk

Oil Futures Fall As Iran Risk Premium Fades -- Market Talk

15 sty 2026, 19:26 UTC

Market Talk

Silver Closes at Fresh High -- Market Talk

15 sty 2026, 18:29 UTC

Major Market Movers

Agenus Falls After $141M Zydus Deal Closes

15 sty 2026, 18:20 UTC

Earnings

Wall Street Powers Nation's Biggest Banks to Record Year -- WSJ

15 sty 2026, 17:56 UTC

Market Talk

Earnings

U.S. Bank Results Look Encouraging for European Peers -- Market Talk

15 sty 2026, 17:20 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Auto & Transport Roundup: Market Talk

15 sty 2026, 17:20 UTC

Market Talk

Health Care Roundup: Market Talk

15 sty 2026, 17:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

15 sty 2026, 17:02 UTC

Acquisitions, Mergers, Takeovers

KBC Group Completes Acquisition of 98.45% Stake in 365.bank From J&T Finance Group

Peer Comparison

Price change

Syndax Pharmaceuticals Inc Forecast

Price Target

By TipRanks

82.42% upside

12 Months Forecast

Average 39.11 USD 82.42%

High 56 USD

Low 27 USD

Based on 10 Wall Street analysts offering 12 month price targets forSyndax Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

10 ratings

Buy

Hold

Sell

Based on 10 analysts giving stock ratings to Syndax Pharmaceuticals Inc - Dist in the past 3 months.

Technical Score

By Trading Central

9.91 / 14.15Support & Resistance

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

There is one bearish event.

Sentiment

By Acuity

161 / 361 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.